January 3, 2018 / 2:03 PM / a year ago

BRIEF-Spark Therapeutics Announces Programs To Improve Patient Access To LUXTURNA

Jan 3 (Reuters) - Spark Therapeutics Inc:

* SPARK THERAPEUTICS ANNOUNCES FIRST-OF-THEIR-KIND PROGRAMS TO IMPROVE PATIENT ACCESS TO LUXTURNA™ (VORETIGENE NEPARVOVEC-RZYL), A ONE-TIME GENE THERAPY TREATMENT

* SPARK THERAPEUTICS INC - ALSO HAS REACHED AN AGREEMENT IN PRINCIPLE WITH AFFILIATES OF EXPRESS SCRIPTS TO ENABLE INNOVATIVE CONTRACTING MODEL

* SPARK THERAPEUTICS INC - IN ACTIVE DISCUSSIONS WITH OTHER COMMERCIAL INSURERS REGARDING THE OFFERING

* SPARK THERAPEUTICS- REACHED DEAL WITH HARVARD PILGRIM TO MAKE LUXTURNA AVAILABLE UNDER OUTCOMES-BASED REBATE ARRANGEMENT & INNOVATIVE CONTRACTING MODEL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below